Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study.

British Journal of Cancer
J BennounaJ-Y Douillard

Abstract

A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum-based regimen. The objectives were to assess efficacy in terms of tumour response rate (primary end point), duration of response, progression-free survival (PFS) and overall survival (OS), and to evaluate the toxicity associated with this treatment. Patients with advanced NSCLC with progressive disease having failed prior platinum-based first-line treatment for advanced disease. Five responses out of the 63 treated patients were documented by WHO criteria and validated by an independent panel review (IRP), yielding a response rate of 7.9% (95% CI: 2.6-17.6) in the intent-to-treat analysis and 8.3% (95% CI: 2.8-18.4) in the evaluable population. Disease control was achieved in 35 out of 60 evaluable patients (58.3%). The median duration of response (complete response+partial response), according to modified WHO criteria was 7.8 months (95% CI: 4.6-NR). Median PFS was 2.6 months (95% CI: 1.4-3.8), and the median survival was 7.0 months (95% CI: 5.8-9.2). Grades 3-4 neutropenia was reported in 50% of patients; febrile neutropenia was ...Continue Reading

References

Aug 12, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·B BiesmaP E Postmus
Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B T HillA Kruczynski
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BennounaM Marty
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group

❮ Previous
Next ❯

Citations

May 14, 2008·Expert Opinion on Pharmacotherapy·Vittorio Gebbia
Mar 28, 2008·Expert Opinion on Investigational Drugs·Adrian Yun-San YipLouis Wing-Cheong Chow
May 2, 2008·Expert Opinion on Investigational Drugs·Robert O Carlson
Apr 29, 2011·Expert Opinion on Drug Safety·Fabio A B SchutzToni K Choueiri
Sep 19, 2007·Expert Opinion on Emerging Drugs·Enriqueta FelipRafael Rosell
Nov 3, 2016·Expert Opinion on Investigational Drugs·C GenovaF Grossi
Jun 30, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John S Ng
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maciej KrzakowskiJean-Yves Douillard
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Denis C TalbotPierre Ruffié
Jan 4, 2017·Therapeutic Advances in Urology·Holger GerullisThorsten Holger Ecke
Sep 11, 2014·Journal of Applied Clinical Medical Physics·Terence T SioKenneth R Olivier
Feb 6, 2009·Expert Review of Anticancer Therapy·Patrick G Morris, Monica N Fornier
Oct 27, 2011·Anti-cancer Drugs·Luis Miguel Anton AparicioGuadalupe Aparicio Gallego
Jan 25, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Terence T SioUzair B Chaudhary
Mar 8, 2008·The Oncologist·Thomas E Stinchcombe, Mark A Socinski
Jan 8, 2016·Current Opinion in Oncology·Cesare Gridelli, Paola Claudia Sacco
Aug 25, 2017·Expert Opinion on Emerging Drugs·Paola Claudia Sacco, Cesare Gridelli
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick G Morris, Monica N Fornier
Apr 15, 2019·Bulletin du cancer·Nadine Houédé, Gérard Milano
Dec 11, 2007·Biochimica Et Biophysica Acta·Barbara T McGroganAmanda McCann

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Software Mentioned

SAS®

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.